Wall Street analyst estimates for Lucid Diagnostics Inc. (LUCD): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.04 | ||
| 2026-08-13 | $-0.06 | $-0.06 | -5.9% |
| 2026-05-14 | $-0.07 | $-0.05 | -40.0% |
| 2026-03-25 | $-0.10 | $-0.07 | -42.9% |
| 2025-11-12 | $-0.10 | $-0.06 | -66.7% |
| 2025-08-13 | $-0.10 | $-0.09 | -11.1% |
| 2025-05-14 | $-0.16 | $-0.09 | -77.8% |
| 2025-03-24 | $-0.19 | $-0.15 | -26.7% |
Valuation Ratios
| Price / Book | 13.87 |
| EV / EBITDA | -3.32 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | $500000 | $377000 | $2.4M | $4.3M | $4.7M |
| Cost of Revenue | 0 | 0 | 0 | $585000 | $3.6M | $8.5M | $8.3M | $7.5M |
| Gross Profit | 0 | 0 | 0 | -$85000 | -$3.2M | -$6.0M | -$3.9M | -$2.8M |
| Research & Development | $715629 | $3.5M | $5.4M | $9.3M | $11.5M | $7.3M | $6.0M | $5.68B |
| Selling, General & Admin | $615428 | $958722 | $2.8M | $18.0M | $39.8M | $35.7M | $36.62B | $41.58B |
| Operating Expenses | $1.1M | $4.4M | $8.3M | $27.3M | $52.9M | $42.4M | $42.1M | $46.8M |
| Operating Income | -$1.1M | -$4.4M | -$8.3M | -$27.4M | -$56.2M | -$48.5M | -$46.1M | -$49.6M |
| EBITDA | $562957 | 0 | $482 | -$27.4M | -$54.2M | -$49.8M | -$44.3M | -$57.1M |
| Interest Expense | 0 | 0 | 0 | $659000 | $8000 | $416000 | $26000 | $22000 |
| Pre-tax Income | -$1.1M | -$4.4M | -$8.3M | -$28.1M | -$56.2M | -$52.7M | -$45.5M | -$58.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$1.1M | -$4.4M | -$8.3M | -$28.1M | -$56.2M | -$52.7M | -$45.5M | -$58.0M |
| EPS | $-0.03 | $-0.12 | $-0.22 | $-0.78 | $-1.55 | $-1.26 | $-1.05 | $-0.69 |
| EPS (Diluted) | $-0.03 | $-0.12 | $-0.22 | $-0.78 | $-1.55 | $-1.26 | $-1.05 | $-0.69 |
| Shares Outstanding (Diluted) | $37.0M | $37.0M | $37.0M | $36.1M | $36.2M | $41.8M | $50.5M | $101.9M |
Price
| Price | $0.78 |
| Market Cap | $149M |
| Exchange | NASDAQ |
| Country | US |
Related companies: APYX · AVR · IRD · IXHL · OWLT · RCEL · RPID
Explore sector: Healthcare · Medical - Devices
More sections of LUCD: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks